RT Journal Article
SR Electronic
T1 Clinical and immunological factors that distinguish COVID-19 from pandemic influenza A(H1N1)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20170761
DO 10.1101/2020.08.10.20170761
A1 Choreño-Parra, José Alberto
A1 Jiménez-Álvarez, Luis Armando
A1 Cruz-Lagunas, Alfredo
A1 Rodríguez-Reyna, Tatiana Sofía
A1 Ramírez-Martínez, Gustavo
A1 Sandoval-Vega, Montserrat
A1 Hernández-García, Diana Lizzeth
A1 Choreño-Parra, Eduardo M.
A1 Balderas-Martínez, Yalbi I.
A1 Martinez-Sanchez, Mariana Esther
A1 Márquez-García, Eduardo
A1 Shiutto, Edda
A1 Moreno-Rodríguez, José
A1 Barreto-Rodríguez, José Omar
A1 Vázquez-Rojas, Hazel
A1 Centeno-Sáenz, Gustavo Iván
A1 Alvarado-Peña, Néstor
A1 Salinas-Lara, Citlaltepetl
A1 Sanchez-Garibay, Carlos
A1 Hernández, Gabriela
A1 Mendoza-Milla, Criselda
A1 Domínguez, Andrea
A1 Granados, Julio
A1 Mena-Hernández, Lula
A1 Pérez-Buenfil, Luis Ángel
A1 Domínguez-Cheritt, Guillermo
A1 Cabello-Gutiérrez, Carlos
A1 Luna, Cesar
A1 Salas-Hernández, Jorge
A1 Santillán-Doherty, Patricio
A1 Regalado, Justino
A1 Hernández-Martínez, Angélica
A1 Orozco, Lorena
A1 García-Latorre, Ethel Awilda
A1 Hernández-Cárdenas, Carmen M.
A1 Khader, Shabaana A.
A1 Zlotnik, Albert
A1 Zúñiga, Joaquín
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.10.20170761.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a global health threat with the potential to cause severe disease manifestations in the lungs. Although clinical descriptions of COVID-19 are currently available, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological characteristics of patients with COVID-19 and pandemic influenza A(H1N1). We observed a higher frequency of respiratory symptoms, increased tissue injury markers, a histological pattern of alveolar pneumonia, and higher levels of IL-1RA, TNF-α, CCL3, G-CSF, APRIL, sTNF-R1, sTNF-R2, sCD30, and sCD163 in influenza patients. Conversely, dry cough, gastrointestinal symptoms, interstitial lung pathology, increased Th1 (IL-12, IFN-γ) and Th2 (IL-4, IL-5, IL-10, IL-13) cytokine levels, along with IL-1β, IL-6, CCL11, VEGF, TWEAK, TSLP, MMP-1, and MMP-3, were observed in COVID-19 cases. We demonstrated the diagnostic potential of some clinical and immune factors to differentiate COVID-19 from pandemic influenza A(H1N1). Our data suggest that SARS-CoV-2 induces a dysbalanced polyfunctional inflammatory response that is different from the immune response against influenza. These findings might be relevant for the upcoming 2020-2021 influenza season, which is projected to be historically unique due to its convergence with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJAPC was supported by the National Council of Science and Technology of Mexico to achieve (CONACyT) his PhD degree (CONACyT-CVU 737347). The current study was supported by institutional research funds of INER and by research contracts: SECTEI/050/2020, Secretaria de Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico (SECTEI CDMX); FORDECyT/10SE/2020/05/14-06 and FORDECyT/10SE/2020/05/14-07 from the Fondo Institucional de Fomento Regional para el Desarrollo Cientifico y Tecnologico y de Innovacion (FORDECyT) of the CONACyT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ, approval number: 3349) and the Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER, approval number: B28-16 and B09-20) in Mexico City approved the study. All participants or their legal guardians provided written informed consent in accordance with the Declaration of Helsinki for Human Research. Clinical samples were managed according to the Mexican Constitution law NOM-012-SSA3-2012, which establishes the criteria for the execution of clinical investigations in humans.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe databases used in the current study are available from the corresponding author on reasonable request